# Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

> **NCT03433703** · PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03433703
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-26
- **Primary completion:** 2019-01-07
- **Final completion:** 2019-01-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.
- **Last updated:** 2019-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03433703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03433703, "Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03433703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*